In patients diagnosed with advanced non-small cell lung cancer (NSCLC) carrying the KRASG12C mutation, sotorasib (AMG510 from AMGEN Inc.)and adagrasib (MRTX849 from MIRATY Inc.), both KRAS mutant specific G12C inhibitors, have exhibited significant efficacy with objective response rates of 37% and 45%, and disease control rates of 81% and 96%, respectively (Dhillon, 2023). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.